Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma

A SIE, SIES, and GITMO consensus paper

Pier Luigi Zinzani, Paolo Corradini, Maurizio Martelli, Giorgio Minotti, Stefano Oliva, Michele Spina, Giovanni Barosi, Sante Tura

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: In this paper, we present a review of critical concepts and research perspectives and produce recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion from an expert panel appointed by the Italian Society of Hematology and the affiliate societies, Società Italiana di Ematologia Sperimentale and Gruppo Italiano Trapianto di Midollo Osseo. Methods: Recommendations were produced using the Delphi process. Scientific evidence on pixantrone efficacy was analyzed using Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) methodology in the areas where at least one randomized trial was published. The following key issues were addressed for practical recommendations: pixantrone monotherapy in aggressive relapsed or refractory non-Hodgkin B-cell lymphomas and toxicity risk management in patients candidates to pixantrone. Results and conclusions: After a balanced and value-oriented discussion, the panel agreed that the benefit/risk profile was in favor of pixantrone in the treatment of adult patients with multiply relapsed or refractory aggressive NHL B-cell lymphomas. Pixantrone was deemed to be contraindicated in patients with uncontrolled cardiovascular disease. Despite a low rate of cardiotoxicity of pixantrone reported in clinical trials, the panel recommended that all patients receiving pixantrone should undergo periodical cardiac monitoring.

Original languageEnglish
JournalEuropean Journal of Haematology
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Non-Hodgkin's Lymphoma
Research
B-Cell Lymphoma
Therapeutics
pixantrone
Risk Management
Hematology
Cardiovascular Diseases
Clinical Trials

Keywords

  • GRADE methodology
  • Guidelines
  • Non-Hodgkin lymphoma
  • Pixantrone

ASJC Scopus subject areas

  • Hematology

Cite this

@article{408f7a4a6f3548e8a1ebd5b2cd1c8e6b,
title = "Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: A SIE, SIES, and GITMO consensus paper",
abstract = "Objectives: In this paper, we present a review of critical concepts and research perspectives and produce recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion from an expert panel appointed by the Italian Society of Hematology and the affiliate societies, Societ{\`a} Italiana di Ematologia Sperimentale and Gruppo Italiano Trapianto di Midollo Osseo. Methods: Recommendations were produced using the Delphi process. Scientific evidence on pixantrone efficacy was analyzed using Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) methodology in the areas where at least one randomized trial was published. The following key issues were addressed for practical recommendations: pixantrone monotherapy in aggressive relapsed or refractory non-Hodgkin B-cell lymphomas and toxicity risk management in patients candidates to pixantrone. Results and conclusions: After a balanced and value-oriented discussion, the panel agreed that the benefit/risk profile was in favor of pixantrone in the treatment of adult patients with multiply relapsed or refractory aggressive NHL B-cell lymphomas. Pixantrone was deemed to be contraindicated in patients with uncontrolled cardiovascular disease. Despite a low rate of cardiotoxicity of pixantrone reported in clinical trials, the panel recommended that all patients receiving pixantrone should undergo periodical cardiac monitoring.",
keywords = "GRADE methodology, Guidelines, Non-Hodgkin lymphoma, Pixantrone",
author = "Zinzani, {Pier Luigi} and Paolo Corradini and Maurizio Martelli and Giorgio Minotti and Stefano Oliva and Michele Spina and Giovanni Barosi and Sante Tura",
year = "2016",
doi = "10.1111/ejh.12768",
language = "English",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma

T2 - A SIE, SIES, and GITMO consensus paper

AU - Zinzani, Pier Luigi

AU - Corradini, Paolo

AU - Martelli, Maurizio

AU - Minotti, Giorgio

AU - Oliva, Stefano

AU - Spina, Michele

AU - Barosi, Giovanni

AU - Tura, Sante

PY - 2016

Y1 - 2016

N2 - Objectives: In this paper, we present a review of critical concepts and research perspectives and produce recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion from an expert panel appointed by the Italian Society of Hematology and the affiliate societies, Società Italiana di Ematologia Sperimentale and Gruppo Italiano Trapianto di Midollo Osseo. Methods: Recommendations were produced using the Delphi process. Scientific evidence on pixantrone efficacy was analyzed using Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) methodology in the areas where at least one randomized trial was published. The following key issues were addressed for practical recommendations: pixantrone monotherapy in aggressive relapsed or refractory non-Hodgkin B-cell lymphomas and toxicity risk management in patients candidates to pixantrone. Results and conclusions: After a balanced and value-oriented discussion, the panel agreed that the benefit/risk profile was in favor of pixantrone in the treatment of adult patients with multiply relapsed or refractory aggressive NHL B-cell lymphomas. Pixantrone was deemed to be contraindicated in patients with uncontrolled cardiovascular disease. Despite a low rate of cardiotoxicity of pixantrone reported in clinical trials, the panel recommended that all patients receiving pixantrone should undergo periodical cardiac monitoring.

AB - Objectives: In this paper, we present a review of critical concepts and research perspectives and produce recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion from an expert panel appointed by the Italian Society of Hematology and the affiliate societies, Società Italiana di Ematologia Sperimentale and Gruppo Italiano Trapianto di Midollo Osseo. Methods: Recommendations were produced using the Delphi process. Scientific evidence on pixantrone efficacy was analyzed using Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) methodology in the areas where at least one randomized trial was published. The following key issues were addressed for practical recommendations: pixantrone monotherapy in aggressive relapsed or refractory non-Hodgkin B-cell lymphomas and toxicity risk management in patients candidates to pixantrone. Results and conclusions: After a balanced and value-oriented discussion, the panel agreed that the benefit/risk profile was in favor of pixantrone in the treatment of adult patients with multiply relapsed or refractory aggressive NHL B-cell lymphomas. Pixantrone was deemed to be contraindicated in patients with uncontrolled cardiovascular disease. Despite a low rate of cardiotoxicity of pixantrone reported in clinical trials, the panel recommended that all patients receiving pixantrone should undergo periodical cardiac monitoring.

KW - GRADE methodology

KW - Guidelines

KW - Non-Hodgkin lymphoma

KW - Pixantrone

UR - http://www.scopus.com/inward/record.url?scp=84993660464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993660464&partnerID=8YFLogxK

U2 - 10.1111/ejh.12768

DO - 10.1111/ejh.12768

M3 - Article

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

ER -